137 related articles for article (PubMed ID: 110947)
1. A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thio-tepa.
Nocks BN; Nieh PT; Prout GR
J Urol; 1979 Jul; 122(1):27-9. PubMed ID: 110947
[TBL] [Abstract][Full Text] [Related]
2. The effect of intravesical thio-tepa on normal and tumor urothelium.
Nieh PT; Daly JJ; Heaney JA; Heney NM; Prout GR
J Urol; 1978 Jan; 119(1):59-61. PubMed ID: 413937
[TBL] [Abstract][Full Text] [Related]
3. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Brosman SA
J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic effect of triethylenethiophosphoramide on the recurrence rate of superficial bladder tumors.
Mukamel E; Zitron S; Nissenkorn I; Servadio C
Isr J Med Sci; 1980; 16(9-10):714-6. PubMed ID: 6776072
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
Hirao Y; Okajima E; Ozono S; Samma S; Sasaki K; Hiramatsu T; Babaya K; Watanabe S; Maruyama Y
Cancer Chemother Pharmacol; 1992; 30 Suppl():S26-30. PubMed ID: 1394812
[TBL] [Abstract][Full Text] [Related]
6. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ
J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488
[TBL] [Abstract][Full Text] [Related]
7. Treatment of superficial bladder tumors in a controlled trial with thio-TEPA versus adriamycin.
Horn Y; Eidelman A; Walach N; Yuval E; Markowitz A
J Surg Oncol; 1984 Sep; 27(1):67-9. PubMed ID: 6434883
[TBL] [Abstract][Full Text] [Related]
8. Intravesical thio-tepa: a study of 3H-thymidine uptake in normal urothelium and FANFT-induced tumors in rats.
Nieh PT; Daly JJ; Irwin RJ; Prout GR
Invest Urol; 1979 May; 16(6):486-8. PubMed ID: 109416
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug sensitivity in vitro in the bladder cancer cell line, KK-47 and prophylactic use of carbazilquinone and urokinase in bladder cancer.
Hisazumi H; Uchibayashi T; Katoh M; Kobayashi T; Nakajima K; Naitoh K; Misaki T; Kuroda K
Urol Res; 1981; 9(5):231-5. PubMed ID: 7029855
[TBL] [Abstract][Full Text] [Related]
10. The effects of intravesical instillation of Thio-Tepa on the recurrence rate of bladder tumors.
Asahi T; Matsumura Y; Tanahashi T; Yoshimoto J; Kaneshige T; Fujita Y; Ohmori H
Acta Med Okayama; 1980 Feb; 34(1):43-9. PubMed ID: 6446839
[TBL] [Abstract][Full Text] [Related]
11. The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Hisazumi H; Uchibayashi T; Naito K; Misaki T; Miyazaki K
J Urol; 1975 Sep; 114(3):394-8. PubMed ID: 806708
[TBL] [Abstract][Full Text] [Related]
12. The prophylactic use of Thio-TEPA, an adjuvant in the treatment of bladder tumours.
Dobrzecki W; Kaczmarek A
Int Urol Nephrol; 1977; 9(2):145-9. PubMed ID: 412808
[TBL] [Abstract][Full Text] [Related]
13. [Thio-tepa treatment for prevention of recurrence of surgically treated bladder tumors].
Neagoe M
Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1980; 29(4):259-65. PubMed ID: 6457322
[TBL] [Abstract][Full Text] [Related]
14. Intravesical chemotherapy in a controlled trial with thio-tepa versus doxorubicin hydrochloride.
Horn Y; Eidelman A; Walach N; Ilian M
J Urol; 1981 May; 125(5):652-4. PubMed ID: 6785455
[No Abstract] [Full Text] [Related]
15. Unanticipated vesicoureteral reflux: a possible sequela of long-term thio-tepa instillations to the bladder.
Mukamel E; Glanz I; Nissenkorn I; Cytron S; Servadio C
J Urol; 1982 Feb; 127(2):245-6. PubMed ID: 6801270
[TBL] [Abstract][Full Text] [Related]
16. Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder.
Gavrell GJ; Lewis RW; Meehan WL; Leblanc GA
J Urol; 1978 Oct; 120(4):410-1. PubMed ID: 100615
[TBL] [Abstract][Full Text] [Related]
17. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
18. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
Br J Urol; 1985 Dec; 57(6):680-5. PubMed ID: 2867800
[TBL] [Abstract][Full Text] [Related]
19. Does intravesical chemotherapy prevent invasive bladder cancer?
Green DF; Robinson MR; Glashan R; Newling D; Dalesio O; Smith PH
J Urol; 1984 Jan; 131(1):33-5. PubMed ID: 6418897
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
